Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Preferred Stock [Member]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series A Preferred Stock [Member]
Common Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Series A Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series B Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2019 $ (18,655)       $ 52,809 $ 35,228 $ 65,222 $ 2       $ 7,354       $ (628) $ (178,642)
Beginning balance, shares at Dec. 31, 2019 [1]         21,615,723 8,306,818 12,804,176 17,602,594                  
Exercise of stock options 6                     6          
Exercise of stock options, shares [1]               4,351                  
Stock compensation expense 1,451                     1,451          
Net loss (Restated) (22,340)                               (22,340)
Foreign currency translation adjustments 30                             30  
Ending balance at Sep. 30, 2020 (39,508)       $ 52,809 $ 35,228 $ 65,222 $ 2       8,811       (598) (200,982)
Ending balance, shares at Sep. 30, 2020 [1]         21,615,723 8,306,818 12,804,176 17,606,945                  
Beginning balance at Jun. 30, 2020 (32,325)       $ 52,809 $ 35,228 $ 65,222 $ 2       8,276       (504) (193,358)
Beginning balance, shares at Jun. 30, 2020 [1]         21,615,723 8,306,818 12,804,176 17,604,528                  
Exercise of stock options 4                     4          
Exercise of stock options, shares [1]               2,417                  
Stock compensation expense 531                     531          
Net loss (Restated) (7,624)                               (7,624)
Foreign currency translation adjustments (94)                             (94)  
Ending balance at Sep. 30, 2020 (39,508)       $ 52,809 $ 35,228 $ 65,222 $ 2       8,811       (598) (200,982)
Ending balance, shares at Sep. 30, 2020 [1]         21,615,723 8,306,818 12,804,176 17,606,945                  
Beginning balance at Dec. 31, 2020 (48,736)       $ 52,809 $ 35,228 $ 65,222 $ 2       10,131       (982) (211,146)
Beginning balance, shares at Dec. 31, 2020 [1]         21,615,723 8,306,818 12,804,176 17,664,015                  
Exercise of stock options 1,065                     1,065          
Exercise of stock options, shares [1]               799,901                  
Stock compensation expense 6,600                     6,600          
Issuance of shares to FP Lenders (Note 6) 22,868             $ 1       22,868          
Issuance of shares to FP Lenders (Note 6), shares [1]               2,468,492                  
Conversion of warrants to common stock 308                     308          
Conversion of warrants to common stock, shares [1]               672,355                  
Conversion of convertible notes to common stock 70,933 $ 52,807 $ 35,227 $ 66,112 $ (52,809) $ (35,228) $ (66,113) $ 4 $ 2 $ 1 $ 1 70,929          
Conversion of convertible notes to common stock, shares [1]   21,615,723 8,306,818 12,951,095 (21,615,723) (8,306,818) (12,951,095) 37,034,620                  
Issuance of common stock upon the reverse recapitalization, net of issuance costs 206,224             $ 4       206,220          
Issuance of common stock upon the reverse recapitalization, net of issuance costs, shares [1]               44,288,129                  
Contingent earnout liability upon closing of the merger (Restated) (58,274)                     (58,274)          
Exercise of series C preferred warrants       $ 891     $ 891                    
Exercise of series C preferred warrants, shares [1]             146,919                    
Net loss (Restated) (102,668)                               (102,668)
Foreign currency translation adjustments 791                             791  
Ending balance at Sep. 30, 2021 100,003       $ 0 $ 0 $ 0 $ 15       413,993       (191) (313,814)
Ending balance, shares at Sep. 30, 2021 [1]         0 0 0 145,801,148                  
Beginning balance at Jun. 30, 2021 (80,699)       $ 52,809 $ 35,228 $ 66,113 $ 2       23,370       (515) (257,706)
Beginning balance, shares at Jun. 30, 2021 [1]         21,615,723 8,306,818 12,951,095 19,212,323                  
Exercise of stock options 392                     392          
Exercise of stock options, shares [1]               229,316                  
Stock compensation expense 2,099                     2,099          
Issuance of shares to FP Lenders (Note 6) 14,804             $ 1       14,803          
Issuance of shares to FP Lenders (Note 6), shares [1]               1,490,769                  
Conversion of warrants to common stock 308                     308          
Conversion of warrants to common stock, shares [1]               672,355                  
Conversion of convertible notes to common stock 70,933       $ (52,809) $ (35,228) $ (66,113) $ 4 $ 2 $ 1 $ 1 70,929 $ 52,807 $ 35,227 $ 66,112    
Conversion of convertible notes to common stock, shares [1]         (21,615,723) (8,306,818) (12,951,095) 37,034,620 21,615,723 8,306,818 12,951,095            
Issuance of common stock upon the reverse recapitalization, net of issuance costs 206,224             $ 4       206,220          
Issuance of common stock upon the reverse recapitalization, net of issuance costs, shares [1]               44,288,129                  
Contingent earnout liability upon closing of the merger (Restated) (58,274)                     (58,274)          
Net loss (Restated) (56,108)                               (56,108)
Foreign currency translation adjustments 324                             324  
Ending balance at Sep. 30, 2021 $ 100,003       $ 0 $ 0 $ 0 $ 15       $ 413,993       $ (191) $ (313,814)
Ending balance, shares at Sep. 30, 2021 [1]         0 0 0 145,801,148                  
[1] The shares of the Company’s common and convertible preferred stock, prior to the Merger (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 1.7058 established in the Merger as described in Note 3.